Ferrari et al 2026 — Dahl SS rat as predictive FM animal model + metformin efficacy
One-paragraph summary
Methodological landmark for FM animal-model standardization. The authors validate the Dahl salt-sensitive (SS) rat as a predictive animal model of human fibromyalgia using a multivariate statistical tool — the Fibromyalgia Analog Model (FAM) index — that quantifies the magnitude of FM-like traits across multiple readouts (pain, mood, fatigue analogues) into a single composite score. Crucially, FAM scores are higher in female SS rats than in males (P<0.0001), matching the human 3:1-9:1 female predominance. Predictive validity is then established by testing the model against agents of known human-FM efficacy: milnacipran and pregabalin (FDA-approved for FM, both P<0.0001 in both sexes) reduce FAM scores, while indomethacin and the µ-opioid agonist DAMGO show limited efficacy (P=0.0239 and P=0.0523 respectively) — matching the relatively poor performance of NSAIDs and opioids in human FM. Metformin (P<0.0001) and green light exposure (P=0.0034 in males, P=0.0002 in females) significantly reduce FAM scores, providing predictive-model-level evidence that both investigational therapies are likely to translate to human FM efficacy. For the project, this is methodologically consequential — the Dahl SS rat + FAM index becomes a candidate validation tool for any future FM cure-path animal work, including Q40 wet-lab follow-up. It is also the third converging line of preclinical evidence supporting the v0.3 §12.9 metformin arm (alongside the AboTaleb pair of papers).
Claims as triples
metformin — modulates → widespread_pain[evidence: FAM-index reduction in Dahl SS rats, P<0.0001; confidence: emerging]dahl_ss_rat — bridges → fm_central_only[evidence: predictive validity demonstrated via FDA-approved FM positive controls + matched response pattern; confidence: established (model validation)]green_light_exposure — modulates → widespread_pain[evidence: FAM-index reduction P=0.0034 (males) / P=0.0002 (females); confidence: emerging]milnacipran — modulates → widespread_pain[evidence: positive control validation; confidence: established (reinforces existing edge)]pregabalin — modulates → widespread_pain[evidence: positive control validation; confidence: established (reinforces existing edge)]
Methods note
Animal-model validation study. Strain: Dahl salt-sensitive (SS) rat; both sexes. Multi-readout phenotyping: pain (mechanical allodynia, thermal hyperalgesia or equivalent), mood-related behavior, fatigue analogue. Composite scoring via the Fibromyalgia Analog Model (FAM) index — multivariate statistical tool aggregating individual readouts into a single FM-trait score. Predictive validity: established by testing FDA-approved FM agents (milnacipran, pregabalin) and known-poorly-effective FM agents (indomethacin NSAID, DAMGO µ-opioid) and confirming the SS rat's response pattern matches human clinical efficacy. Investigational therapy testing: metformin and green-light exposure as cure-path candidates. Statistical analysis: t-tests / ANOVA with sex stratification; reported P-values for each agent in each sex.
Limitations
- Animal model — translation to human FM remains by analogy. FAM-index-based composite scoring is a convergence-of-readouts approach, but FM in humans is heterogeneous in symptom pattern and may not be fully captured by a single composite score.
- Predictive validity demonstrated by cross-sectional response to known agents, not by longitudinal-disease-progression dynamics. The Daban 2026 trigger-dynamics framing (cognitive-load + emotional-stress + recovery-failure) is not yet operationalized in the SS rat.
- The model's mechanism is not fully specified. Why Dahl SS rats develop FM-like traits is partly characterized (likely combination of salt-sensitive-hypertension biology + inflammatory pathway differences) but does not directly map onto the project's three-hypothesis architecture. The model may capture H3 substrate phenomenology without testing H1 (HERV-mito loop) or H3 (autoimmune-microbiome chain) mechanisms.
- Green light exposure, while a positive readout, is a non-pharmacological intervention with unclear mechanism specification that doesn't currently fit any of the project's three hypotheses cleanly.
Open questions raised
- Does the Dahl SS rat carry HERV-equivalent reactivation or cGAS-STING activation under FM-trait induction? If so, the model could be used to test the resveratrol / temelimab cure-path arms.
- Is the female-higher-FAM-score finding driven by estrogen, by X-chromosome dosage, or by sex-as-biological-variable broader effects? Cross-comparison with the AboTaleb 2024 Cells sex-specific neurotransmitter finding could resolve.
- Does metformin reduce FAM scores via the same mechanism in both sexes (the SS rat paper does not stratify mechanism by sex), or via the sex-specific neurotransmitter pattern observed in the AboTaleb 2024 Cells paper?
Triangulation notes
- Methodologically consequential for the project. The Dahl SS rat + FAM index becomes a candidate platform for cure-path animal validation across multiple v0.3 cure-path arms: BASIS-FM precursor work, MCAS-stratified cromolyn preclinical work, resveratrol Hypothesis 1 testing. Future Q40 wet-lab follow-up should consider the SS rat as an FM-relevant validation model.
- Third converging line of preclinical evidence for the v0.3 §12.9 metformin arm. Joining AboTaleb & Alghamdi 2024 review (mechanism framing) and AboTaleb et al 2024 Cells (mouse FM model). The arm is now supported by three independent FM-relevant preclinical lines from two independent groups.
- Cross-validation with FDA-approved FM positive controls strengthens the green-light + metformin findings as cure-path candidates beyond what either positive result alone could provide. The model's predictive validity is the load-bearing claim that lets us extrapolate to human FM with reasonable confidence.
- PAIN peer-reviewed publication. Promotes the methodological framework to peer-review tier.
Bridges
- B17 strengthened — metformin / AMPK-activator class ↔ FM via predictive-validity-demonstrated animal model.
- Opens a methodological bridge to the broader FM animal-model literature: future cross-validation of the SS rat against the reserpine model (AboTaleb 2024 Cells) and the peripheral-MC model (the 2024 Eur J Pharmacol paper) would clarify which FM-relevant biology each captures.